Procter & Gamble is about to report earnings. Here’s what to expect

Procter & Gamble is about to report earnings. Here’s what to expect


Bottles of Tide detergent, a Procter & Gamble product, are displayed for sale in a pharmacy on July 30, 2020 in Los Angeles, California.

Mario Tama | Getty Images

Procter & Gamble is expected to report its fiscal third-quarter earnings before the bell.

Here’s what Wall Street analysts are expecting, based on a Refinitiv survey:

  • Earnings per share: $1.29 expected
  • Revenue: $18.73 billion expected

Consumer goods giant P&G may serve as a bellwether for investors as costs rise shoppers weigh higher price tags.

So far, price hikes have helped the company preserve profits amid soaring inflation. Products like Oral-B toothbrushes and Gillette razors saw a sales bump last quarter, thanks to price increases. But investors will be watching closely for any changes in consumer behavior as shoppers face elevated prices at the gas pump and in grocery store aisles.

Russia’s invasion of Ukraine has not only intensified inflation in the U.S., but also spurred scrutiny of P&G and other Western companies that operate in Russia. P&G has suspended its Ukrainian operations and scaled back those in Russia. The two countries account for less than 2% of its overall revenue.

For fiscal 2022, P&G is calling for 3% to 4% sales growth and core earnings per share increases of 3% to 6%, according to its latest release. It’s also predicting a $2.6 billion headwind from inflation for the fiscal year.

Shares of P&G have climbed 16% over the last 12 months, giving it a market value of $381 billion.

This is breaking news. Please check back for updates.



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More